Toremifene
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Toremifene: From Breast Cancer to HIV Infectious Disease
One-Sentence Summary
Toremifene is a selective estrogen receptor modulator (SERM), historically used to treat hormone receptor-positive (ER+) metastatic breast cancer in postmenopausal women. The TxGNN model’s top-ranked prediction is HIV Infectious Disease, but this direction is currently supported by 0 clinical trials and only 1 mechanistic/in-vitro publication, and that publication actually concerns anti-cryptococcal (opportunistic infection) activity rather than antiretroviral action — so the evidence for this specific prediction remains weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not derivable from EU regulatory license text (no EU marketing authorization on record); literature evidence in this pack indicates hormone receptor-positive (ER+) metastatic breast cancer in postmenopausal women |
| Predicted New Indication | HIV Infectious Disease |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L4 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data is not available for Toremifene in this Evidence Pack (flagged as a High-severity data gap, DG002). Based on the literature evidence collected across other predicted indications in this pack, Toremifene is known to act as a triphenylethylene SERM that competitively antagonizes the estrogen receptor, which is its well-established mechanism in breast cancer treatment.
The relationship between this known mechanism and the top-ranked prediction (HIV Infectious Disease) is not well supported. The single literature citation attached to this indication (PMID 24520056) actually demonstrates that estrogen receptor antagonists related to tamoxifen and toremifene have anti-cryptococcal fungicidal activity — relevant to an opportunistic infection sometimes seen in AIDS patients, not to HIV viral replication or antiretroviral mechanisms themselves. This suggests the high TxGNN score may reflect a knowledge-graph artifact, where “HIV infection,” “AIDS,” and related opportunistic-infection concepts are semantically clustered together, rather than a genuine mechanistic signal.
Notably, a more biologically plausible (though still preclinical) signal exists further down the ranked list: rank 6, “AIDS” (L4, decision stage S1, “Research Question”), where in-vitro data show Toremifene has antiproliferative activity against AIDS-related Kaposi’s sarcoma cells via TGF-β1 upregulation. If this repurposing avenue is of interest, that indication — not HIV infection itself — is the more defensible starting point for further investigation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24520056 | 2014 | Mechanistic/In vitro | mBio | Estrogen receptor antagonists (toremifene, tamoxifen) bind EF-hand proteins and show anti-cryptococcal (antifungal) activity, synergizing with fluconazole and amphotericin B in vitro; relevant to an AIDS-associated opportunistic infection, not to HIV viral mechanism directly |
EU Market Information
Toremifene currently holds no EU marketing authorization in this dataset (market status: Not Marketed, 0 licenses on record).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Hormonal/targeted antineoplastic therapy (SERM), same pharmacological class as tamoxifen — not a conventional cytotoxic agent |
| Myelosuppression Risk | Low — SERMs are not associated with significant bone marrow suppression, unlike cytotoxic chemotherapy |
| Emetogenicity Classification | Low |
| Monitoring Items | Liver function and serum lipids (per comparative studies with tamoxifen); gynecological/endometrial monitoring given reported increased endometrial cancer risk with long-term antiestrogen therapy |
| Handling Protection | Oral agent; not classified as a hazardous cytotoxic drug requiring special handling precautions under cytotoxic drug handling regulations |
Safety Considerations
Please refer to the SmPC for safety information. (Key warnings, contraindications, and drug–drug interaction data are not available in this Evidence Pack — flagged as a Blocking-severity data gap, DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (HIV Infectious Disease, score 99.41%) lacks direct mechanistic or clinical support — its sole literature citation concerns anti-cryptococcal (opportunistic infection) activity, not antiretroviral action, and no clinical trials exist for this indication. The high similarity score likely reflects semantic clustering between “HIV” and “AIDS”-related concepts in the knowledge graph rather than a genuine biological signal, so evidence is insufficient to advance beyond S0.
To proceed, the following is needed:
- Resolve DG001 (EU/national label warnings and contraindications) and DG002 (confirmed mechanism of action) before any safety review (S1) can begin
- Preclinical studies specifically testing antiretroviral (anti-HIV) activity, rather than activity against opportunistic co-infections
- If pursuing the AIDS-related opportunistic infection signal instead (rank 6, “AIDS,” L4/S1, Research Question — supported by in-vitro Kaposi’s sarcoma and anti-cryptococcal data), further translational research is needed before clinical evaluation
- Clarification of why EU market status shows “Not Marketed” despite an extensive global clinical trial and literature record for Toremifene’s established use in breast cancer (rank 8 in this dataset shows L1 evidence and “Proceed with Guardrails” for that indication) — this discrepancy should be verified against source regulatory data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.